Grid Therapeutics Announces Enrollment of First Patient in Phase 1 Study of GT103 in Refractory NSCLC Patients Read More…
By Harnessing the Power of Human Derived Antibodies,
We’re Innovating Cancer Treatment.
About US
Grid Therapeutics is an emerging clinical stage biotechnology company located in Durham, North Carolina. We have made a commitment to our patients and families to develop better and safer therapeutic antibodies for cancer.
Based on fundamental principles of anti-tumor immunity, Grid Therapeutics has a unique strategy to rapidly and efficiently develop novel tumor-specific therapeutic antibodies for the treatment of multiple cancer types directly from single human B cells.
Keep yourself updated with the latest news from Grid. Check back regularly for new content posted weekly about cancer treatment and the search for a cure!